Cardiac AI: The Billion Dollar Bet on Preventing Heart Events

Stopping one big heart attack or stroke saves a health plan tens of thousands of dollars. That’s why preventative AI is suddenly a huge priority for value-based care organizations. The whole game is shifting from paying for expensive, reactive treatments to proactively managing risk, especially for the high-need, high-cost patients who always drive the lion’s share of spending.

Why Cardiac AI Needs to Prove Its Worth

As we move more into value-based care (VBC), any health AI platform has to be rigorously vetted for what really matters: proven economic and clinical results, not just fancy tech. Investors are getting a lot tougher on vendors, demanding hard numbers on cost savings and better patient health instead of vague promises about ‘efficiency’. The “Consensus Study Report” approach basically confirms what we already know, that a small group of high-need, high-cost patients drives most of the spending, which is exactly why smart AI vendors are laser-focused on this group to head off acute events and generate real savings. Any AI tool that wants a seat at the VBC table has to have this focus.

Viz.ai: Early Detection and the Regulatory Pathway

Viz.ai is a great example of how AI can jump in and prevent a massive bill from a cardiac event by catching it early. Their platform uses computer vision to chew through medical images like CT scans, spotting life-threatening things like large vessel occlusions (LVOs) and pulmonary embolisms (PEs) with incredible speed. Finding these conditions hours ahead of what a human can do on their own improves patient outcomes and also slashes the long-term costs that come with delayed treatment. Viz.ai has done the hard work of getting through the FDA’s regulatory maze, racking up multiple 510(k) Clearances for its SaMD FDA 510(k) database for Viz.ai. For example, their AI for stroke detection got its first FDA clearance way back in 2018, and they’ve been adding more ever since, including a De Novo approval for hypertrophic cardiomyopathy in August 2023 and even 510(k)s for things like quantifying intracerebral hemorrhages in February 2024 and measuring subdural hemorrhages in June 2025. These FDA approvals are a huge de-risking signal for investors because they prove the tech meets tough safety and efficacy standards. Because the Viz.ai platform speeds up the whole diagnosis-to-treatment pipeline, you see shorter hospital stays and lower disability rates, which is what translates directly into major cost savings for payers working under VBC contracts. A single major heart attack or stroke can easily cost anywhere from tens of thousands to over a hundred thousand dollars, so the financial upside of preventing even a few of them is obvious.

Hippocratic AI: Generative AI for Post-Discharge Compliance

While Viz.ai is all about acute detection in the hospital, Hippocratic AI is tackling a different, but just as important, problem: what happens after the patient goes home. They use large language models (LLMs) to make sure patients actually stick to their treatment plans, manage their conditions, and show up for follow-ups. This is a massive point of failure for cardiac patients where a missed pill or a bad diet can land them right back in the hospital. They’ve pulled in a lot of cash from big-name investors like General Catalyst, Avenir Growth, and CapitalG, which is how they hit a $3.5 billion unicorn valuation during their Series C in November 2025 Press releases from General Catalyst, Avenir Growth, and CapitalG regarding Hippocratic AI. In healthcare, where bad information can have disastrous results, their focus on a safety-first LLM is the only responsible way to operate. By automating things like patient education, sending appointment reminders, and even monitoring symptoms with generative AI, Hippocratic AI is basically building a proactive support net to catch problems before they become expensive emergencies. This is a direct shot at the “High-Need, High-Cost Patients Drive Spending” problem because it provides that continuous, smart engagement that’s so often missing once a patient leaves the clinic.

Tempus AI: Genomic and Clinical Data Integration for Predictive Risk

Tempus AI brings a totally different angle to the problem by integrating genomic and clinical data to predict risk before a cardiac event is even on the horizon. They’re mostly known for their work in oncology, but the core idea of mixing multimodal data to predict how a disease will progress and how a patient will respond to treatment is a perfect fit for cardiology. Tempus has been a major force in health AI for a while, and they went public on June 14, 2024, listing on the Nasdaq as “TEM”. That IPO brought in $410.7 million at a $6.1 billion valuation. As of right now, its market cap is sitting around $11.37 billion. So what does this mean for cardiac care? It means you can spot genetic predispositions or early biomarkers which, when you layer in clinical data, can flag a patient for early intervention. This kind of proactive ID lets you roll out targeted preventative measures, everything from lifestyle coaching to early drug therapies, long before an acute event is even a possibility. Being able to predict risk this accurately helps you avoid wasting money on unnecessary interventions for low-risk people and concentrate your resources on the patients who are actually going to benefit, which is the entire point of cost-effectiveness in a VBC world. News reports on Tempus AI IPO and current market performance

The Real Gold Standard: Peer-Reviewed Outcomes Data

For any investor trying to sort through the noise in the health AI market, the only thing that really separates the winners from the losers is hard, peer-reviewed outcomes data. While companies like Viz.ai and Hippocratic AI have cool tech and have raised a lot of money, the real long-term value belongs to whoever can prove, without a doubt, that their product improves patient outcomes and lowers costs. This is exactly why a company like Hello Heart is such a good benchmark. Using its digital therapeutics platform for hypertension and heart disease, Hello Heart has been consistently publishing peer-reviewed studies showing real-world results: lower blood pressure, better medication adherence, and quantifiable savings for health plans. That kind of evidence, published in top medical journals, is exactly what a payer needs to see before they’ll sign a VBC contract. Payers require that level of transparent, scientific validation for these kinds of deals. Without that data, it doesn’t matter how great an AI platform’s tech is or how much money it’s raised. It’s going to have a hard time proving its financial and clinical value in a VBC contract. The AI vendors who will win are the ones who target the top 5 percent of high-cost patients with preventative tools and (this is the important part) back up every single claim with rigorous, peer-reviewed evidence. This commitment to outcomes isn’t just good science. It’s just good business in value-based care.

Methodology Note

I put this analysis together by looking through FDA clearance databases, VC funding announcements and press releases, and general market scuttlebutt about how AI is being used in preventative cardiac care. The focus here is on vendors who are actually aligned with the VBC model by showing they can make a real impact on high-cost patient groups.